NGR peptide is a tumor-homing ligand containing the Asn-Gly-Arg (NGR) motif that selectively binds to CD13/aminopeptidase N receptors overexpressed on tumor vasculature. The cyclic CVLNGRMEC sequence serves as a benchmark, with peptide array screening identifying variants exhibiting up to 5-fold higher binding affinity to CD13-positive cells and negligible binding to negative cell lines. This binding triggers selective impairment of pro-survival signaling pathways, including Ras, Erk, and Akt, while enhancing caspase activation and apoptosis. NGR peptide is widely employed for targeted tumor imaging, such as 68Ga-labeled constructs for microPET, and for directing nanoparticle-based delivery systems to achieve improved cellular uptake and specificity.

DMSO: ≥20.3 mg/mL, Sonication is recommended.